12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fanapt iloperidone regulatory update

EMA's CHMP issued a negative opinion against approval of Vanda's Fanaptum iloperidone to treat schizophrenia. CHMP said the short-term efficacy of the compound was "modest" compared to placebo and that the long-term efficacy has not been "sufficiently...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >